Plasmapheresis for treatment of pulmonary alveolar proteinosis.
Whole lung lavage (WLL) is currently the standard therapy for pulmonary alveolar proteinosis (PAP). Nevertheless, some PAP patients respond poorly to WLL or require it frequently. The present paper reports a patient with autoimmune PAP with persistent disease despite three WLL treatments over 10 months. Plasmapheresis with ten 1.5-L plasma exchanges was performed, which lowered the serum granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody level from 250 microg mL(-1) to 156 microg mL(-1) but did not improve respiratory impairment. Further WLL therapy was required and transiently effective. Serum GM-CSF autoantibody levels declined progressively, reaching a value of 56 microg mL(-1) 80 weeks after completion of plasmapheresis. However, this decrease was not accompanied by clinical improvement and the patient required additional WLL therapy. The results confirm that minor reductions in serum granulocyte-macrophage colony-stimulating factor autoantibody levels from plasmapheresis are not reflected in clinical improvement in the severity of lung disease in pulmonary alveolar proteinosis.
Luisetti
M
M
Clinica Malattie Apparato Respiratorio, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy. m.luisetti@smatteo.pv.it
Rodi
G
G
Perotti
C
C
Campo
I
I
Mariani
F
F
Pozzi
E
E
Trapnell
B C
BC
D000328:Adult; D018893:Bronchoalveolar Lavage; D006801:Humans; D008297:Male; D010956:Plasmapheresis; D011649:Pulmonary Alveolar Proteinosis / Q000175:diagnosis / Q000628:therapy*